


JAK-IN-20

Cat. No.:	HY-143444
CAS No.:	1654776-91-6
Molecular Formula:	C ₂₈ H ₃₀ FN ₇ O ₂
Molecular Weight:	515.58
Target:	JAK
Pathway:	Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC ₅₀ s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo ^[1] .																						
IC₅₀ & Target	JAK1 7 nM (IC ₅₀)	JAK2 5 nM (IC ₅₀)	JAK3 14 nM (IC ₅₀)																				
In Vivo	<p>JAK-IN-20 (compound 32) (3 mg/kg for p.o.; 1 mg/kg for i.v.) shows excellent pharmacokinetics in rats^[1]. JAK-IN-20 (10 mg/kg; p.o.; once a day for 3 days) shows anti-inflammatory effect^[1]. Pharmacokinetic Parameters of JAK-IN-20 in female Sprague Dawley rats^[1].</p> <table border="1"> <thead> <tr> <th>parameter</th> <th>32</th> </tr> </thead> <tbody> <tr> <td>PO Dose (mg/kg)</td> <td>3</td> </tr> <tr> <td>T_{max} (h)</td> <td>0.63(0.25-6)</td> </tr> <tr> <td>C_{max} (µg/mL)</td> <td>7.82±3.68</td> </tr> <tr> <td>AUC_{0-t} (µg.h/mL)</td> <td>80.18±35.44</td> </tr> <tr> <td>T^{1/2},po (h)</td> <td>4.77±1.84</td> </tr> <tr> <td>MRT (h)</td> <td>7.54±2.52</td> </tr> <tr> <td>IV Dose (mg/kg)</td> <td>1</td> </tr> <tr> <td>C₀ (µg/mL)</td> <td>4.70±2.50</td> </tr> <tr> <td>AUC_{0-t} (µg.h/mL)</td> <td>18.89±1.76</td> </tr> </tbody> </table>			parameter	32	PO Dose (mg/kg)	3	T _{max} (h)	0.63(0.25-6)	C _{max} (µg/mL)	7.82±3.68	AUC _{0-t} (µg.h/mL)	80.18±35.44	T ^{1/2} ,po (h)	4.77±1.84	MRT (h)	7.54±2.52	IV Dose (mg/kg)	1	C ₀ (µg/mL)	4.70±2.50	AUC _{0-t} (µg.h/mL)	18.89±1.76
parameter	32																						
PO Dose (mg/kg)	3																						
T _{max} (h)	0.63(0.25-6)																						
C _{max} (µg/mL)	7.82±3.68																						
AUC _{0-t} (µg.h/mL)	80.18±35.44																						
T ^{1/2} ,po (h)	4.77±1.84																						
MRT (h)	7.54±2.52																						
IV Dose (mg/kg)	1																						
C ₀ (µg/mL)	4.70±2.50																						
AUC _{0-t} (µg.h/mL)	18.89±1.76																						

V_{ss} (L/kg) 0.32±0.14

CL (mL/min/kg) 0.85±0.13

$T^{1/2}_{iv}$ (h) 5.16±3.83

MRT (h) 6.69±4.03

%F 100

Wistar rats; 3 mg/kg; p.o. (1% Tween 80 + 99% (0.5%) methyl cellulose in water); 1 mg/kg; i.v. (5% NMP + 5% solutol + 90% normal saline)^[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	7-10 weeks, 250-300g, male wistar rats ^[1]
Dosage:	
Administration:	3 mg/kg for p.o.; 1 mg/kg for i.v.
Result:	Showed fast oral absorption, higher plasma exposure, extended oral half-life and excellent oral bioavailability of 100%.

Animal Model:	Female Sprague Dawley rats (PGPS rat model) ^[1]
Dosage:	10 mg/kg
Administration:	P.o.; once a day; 3 days
Result:	Showed anti-inflammatory effect.

REFERENCES

[1]. Desai J, et al. Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor. Bioorg Med Chem Lett. 2022; 66:128728.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA